Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A concern most hepatitis C patients have after treatment is the possibility of Hep C coming back.
Long-lived memory immune cells continue to provide protection even after antibody levels drop.
A systematic review of hep C treatment outcomes in this population shows they have high cure rates and relatively low reinfection rates.
Researchers followed people with a drug-injection history who had been cured of hepatitis C and were receiving addiction treatment.
Consistent use of medication-assisted treatment for opioid use disorder can apparently reduce this risk.
A study of gay and bi men with HIV in Australia who had been cured of hep C found they associated hep C with injection drug use.
A study conducted in Australia treated people attending a syringe services program.
Researchers used mathematical modeling to analyze the benefits of treating with buprenorphine/naloxone on-site.
HIV-positive men who have sex with men in Western nations historically have a significant risk of contracting hepatitis C through sex.
A look at personal hygiene instruments that may transmit hepatitis C.
Using opioid medication treatment such as methadone appears to lower this risk.
This would hold true even if the hepatitis C vaccine did not provide sterilizing immunity.
Research suggests that individuals receiving opioid replacement therapy have a better chance of beating hep C through this method.
Few people saw their liver disease progress, and there were scant numbers of relapses more than 12 weeks posttreatment in a large study.
Researchers from a German cohort found that the reinfection rate for men who have sex with men was almost 10 percent per year.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.